Physician profile
David Cd Oh
NPI 1730764192
$8,557.82
in general payments reported to CMS, 2019-2025
18 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $809 · 2022: $2,048 · 2023: $3,498 · 2024: $772 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,668 · Travel and Lodging: $22.50 · Education: $11.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,667.77 |
| Travel and Lodging | $22.50 |
| Education | $11.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,733.39 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,325.50 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $872.14 | 2021-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $869.62 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $689.32 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $637.91 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $609.64 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $577.75 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $307.79 | 2022-2023 | Ingrezza |
| Axsome Therapeutics, INC. | $294.85 | 2023 | Auvelity |
| Lundbeck LLC | $291.63 | 2022-2025 | Rexulti |
| Eisai INC. | $124.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $124.25 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $41.17 | 2025 | Xelstrym |
| Avadel Cns Pharmaceuticals, LLC | $23.23 | 2025 | Lumryz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $18.56 | 2025 | Jornay Pm |
| Corium, LLC | $16.19 | 2023 | Azstarys |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.